Citations (67)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Valeria McCarroll. (2023) Mysticizing medicine: incorporating nondualism into the training of psychedelic guides. Interdisciplinary Science Reviews 48:5, pages 752-767.
Read now
Read now
Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira, Bruno Daniel Rasmussen Chaves & Yuan-Pang Wang. (2023) Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis. Journal of Psychoactive Drugs 0:0, pages 1-11.
Read now
Read now
Stanley Wong, An Yi Yu, Nicholas Fabiano, Ofer Finkelstein, Aryan Pasricha, Brett D.M. Jones, Joshua D. Rosenblat, Daniel M. Blumberger, Benoit H. Mulsant & M. Ishrat Husain. (2023) Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders. Journal of Psychoactive Drugs 0:0, pages 1-17.
Read now
Read now
Debora Oliveira, Rodrigo Fontenele, Jeremy Weleff, Mehmet Sofuoglu & Joao P. De Aquino. (2023) Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review of Psychiatry 35:5-6, pages 377-396.
Read now
Read now
Alexandra Arenson, Cynthia I. Campbell & Ilan Remler. (2023) Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder – a narrative review. Journal of Addictive Diseases 0:0, pages 1-11.
Read now
Read now
Matthias Luz & Deborah C. Mash. (2021) Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse. Expert Opinion on Drug Metabolism & Toxicology 17:9, pages 1019-1022.
Read now
Read now
Thomas K. Brown, Geoff E. Noller & Julie O. Denenberg. (2019) Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder. Journal of Psychoactive Drugs 51:2, pages 155-165.
Read now
Read now
Alan K. Davis, Elise Renn, Austin-Marley Windham-Herman, Martin Polanco & Joseph P. Barsuglia. (2018) A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification. Journal of Psychoactive Drugs 50:4, pages 287-297.
Read now
Read now
Benjamin J. Malcolm, Martin Polanco & Joseph P. Barsuglia. (2018) Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine. Journal of Psychoactive Drugs 50:3, pages 256-265.
Read now
Read now
Deborah C. Mash. (2018) Breaking the cycle of opioid use disorder with Ibogaine. The American Journal of Drug and Alcohol Abuse 44:1, pages 1-3.
Read now
Read now
Articles from other publishers (57)
Lianne de Wit, Hester Hendriks, Jacqueline van Engelen, Harm Heusinkveld, Anne Kienhuis, Emiel Rorije, Marjolijn Woutersen, Margriet van der Zee & Suzanne Jeurissen. (2024) New Approach Methodologies (NAMs) for ad hoc human health risk assessment of food and non-food products - Proceedings of a workshop. Regulatory Toxicology and Pharmacology 149, pages 105615.
Crossref
Crossref
Jeremy Weleff, Julio C. Nunes, Gabriel P. A. Costa, Mehmet Sofuoglu, R. Ross MacLean & Joao P. De Aquino. (2024) From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder. British Journal of Clinical Pharmacology.
Crossref
Crossref
Fahd François Hilal, Jerome Jeanblanc, Chloé Deschamps, Mickael Naassila, Olivier Pierrefiche & Sami Ben Hamida. (2024) Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies. Journal of Neural Transmission.
Crossref
Crossref
Agnieszka D. Sekula, Prashanth Puspanathan, Luke Downey & Paul Liknaitzky. (2024) Producing Altered States of Consciousness, Reducing Substance Misuse: A Review of Psychedelic-Assisted Psychotherapy, Transcendental Meditation and Hypnotherapy. Psychoactives 3:2, pages 137-162.
Crossref
Crossref
Juan Pedro Castro-Nin, Diego Serantes, Paola Rodriguez, Bruno Gonzalez, Ignacio Carrera, Pablo Torterolo & Joaquín González. (2024) Noribogaine acute administration in rats promotes wakefulness and suppresses REM sleep. Psychopharmacology.
Crossref
Crossref
Kirsten CherianKenneth Shinozuka, Burton J. TabaacAlejandro ArenasBryce D. BeutlerViviana D. EvansChelsey FasanoOwen S. Muir. (2024) Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine. American Journal of Therapeutics 31:2, pages e133-e140.
Crossref
Crossref
Nicolas G. Glynos, Jacob S. Aday, Daniel Kruger, Kevin F. Boehnke, Stephanie Lake & Philippe Lucas. (2024) Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey. Frontiers in Psychiatry 15.
Crossref
Crossref
Kirsten N. Cherian, Jackob N. Keynan, Lauren Anker, Afik Faerman, Randi E. Brown, Ahmed Shamma, Or Keynan, John P. Coetzee, Jean-Marie Batail, Angela Phillips, Nicholas J. Bassano, Gregory L. Sahlem, Jose Inzunza, Trevor Millar, Jonathan Dickinson, C. E. Rolle, Jennifer Keller, Maheen Adamson, Ian H. Kratter & Nolan R. Williams. (2024) Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine 30:2, pages 373-381.
Crossref
Crossref
Genís Ona, Ingrid Reverte, Giordano N Rossi, Rafael G dos Santos, Jaime EC Hallak, Maria Teresa Colomina & José Carlos Bouso. (2023) Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview. Journal of Psychopharmacology 37:12, pages 1190-1200.
Crossref
Crossref
Boukandou Mounanga Marlaine Michele & Aboughe Angone Sophie. (2023) A review of the mechanisms involved in the neuroprotection and neurotoxicity of Iboga alkaloids. Pharmacological Research - Natural Products 1, pages 100006.
Crossref
Crossref
Andrew A. BolingerNoelle C. AnastasioKathryn A. CunninghamJia Zhou. 2023. 2023 Medicinal Chemistry Reviews. 2023 Medicinal Chemistry Reviews
53
81
.
Lindsay P. Cameron, Joseph Benetatos, Vern Lewis, Emma M. Bonniwell, Alaina M. Jaster, Rafael Moliner, Eero Castrén, John D. McCorvy, Mikael Palner & Argel Aguilar-Valles. (2023)
Beyond the 5-HT
2A
Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action
. The Journal of Neuroscience 43:45, pages 7472-7482.
Crossref
Crossref
Alessio Mosca, Stefania Chiappini, Andrea Miuli, Gianluca Mancusi, Maria Chiara Santovito, Francesco Di Carlo, Mauro Pettorruso, John M. Corkery, Carlos Canessa, Giovanni Martinotti & Massimo Di Giannantonio. (2023) Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A
Systematic Review of the Current Literature. Current Neuropharmacology 21:11, pages 2178-2194.
Crossref
Crossref
Leah M. Salinsky, Christina R. Merritt, Joshua C. Zamora, Juliana L. Giacomini, Noelle C. Anastasio & Kathryn A. Cunningham. (2023) μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges. Frontiers in Pharmacology 14.
Crossref
Crossref
Mary G. Hornick & Ashley Stefanski. (2023) Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder. Frontiers in Pharmacology 14.
Crossref
Crossref
Romain Nardou, Edward Sawyer, Young Jun Song, Makenzie Wilkinson, Yasmin Padovan-Hernandez, Júnia Lara de Deus, Noelle Wright, Carine Lama, Sehr Faltin, Loyal A. Goff, Genevieve L. Stein-O’Brien & Gül Dölen. (2023) Psychedelics reopen the social reward learning critical period. Nature 618:7966, pages 790-798.
Crossref
Crossref
Rayyan Zafar, Maxim Siegel, Rebecca Harding, Tommaso Barba, Claudio Agnorelli, Shayam Suseelan, Leor Roseman, Matthew Wall, David John Nutt & David Erritzoe. (2023) Psychedelic therapy in the treatment of addiction: the past, present and future. Frontiers in Psychiatry 14.
Crossref
Crossref
Deborah C. Mash. (2023) IUPHAR – invited review - Ibogaine – A legacy within the current renaissance of psychedelic therapy. Pharmacological Research 190, pages 106620.
Crossref
Crossref
Jonathan Dickinson. (2023) Transpersonal Intersubjectivity in Ibogaine Experiences: Three cases. Anthropology of Consciousness 34:1, pages 161-180.
Crossref
Crossref
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, Jessica R. Gilbert, Ioline D. Henter & Carlos A. ZarateJr.Jr.. (2023) Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology 226, pages 109422.
Crossref
Crossref
Borja J. Rodríguez‐Cano, Maja Kohek, Genís Ona, Miguel Ángel Alcázar‐Córcoles, Rafael G. dos Santos, Jaime E. C. Hallak & José Carlos Bouso. (2022) Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences. Drug and Alcohol Review 42:2, pages 401-414.
Crossref
Crossref
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, Giulia Abate, Sara Anna Bonini, Gregorio Peron, Emanuela Tirelli, Mariachiara Pucci, Giovanni Ribaudo, Erika Oselladore, Marika Premoli, Alessandra Gianoncelli, Daniela Letizia Uberti & Maurizio Memo. (2023) The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. International Journal of Molecular Sciences 24:2, pages 1329.
Crossref
Crossref
Elliot Marseille, Stefano Bertozzi & James G. Kahn. (2022) The economics of psychedelic-assisted therapies: A research agenda. Frontiers in Psychiatry 13.
Crossref
Crossref
Bruno Ramos Gomes & Luis Fernando Tofoli. (2022) A sacred plant of neuronal effect: the use of ibogaine in addiction treatments in Brazil. Anthropology of Consciousness 33:2, pages 333-357.
Crossref
Crossref
Patrick Köck, Katharina Froelich, Marc Walter, Undine Lang & Kenneth M. Dürsteler. (2022) A systematic literature review of clinical trials and therapeutic applications of ibogaine. Journal of Substance Abuse Treatment 138, pages 108717.
Crossref
Crossref
Nataliya Vorobyeva & Alena A. Kozlova. (2022) Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. Frontiers in Pharmacology 13.
Crossref
Crossref
Margarida L. F. Martins, Paniz Heydari, Wenlong Li, Alejandra Martínez-Chávez, Nikkie Venekamp, Maria C. Lebre, Luc Lucas, Jos H. Beijnen & Alfred H. Schinkel. (2022) Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites. Frontiers in Pharmacology 13.
Crossref
Crossref
Thomas Knuijver, Arnt Schellekens, Maarten Belgers, Rogier Donders, Toon van Oosteren, Kees Kramers & Robbert Verkes. (2021) Safety of ibogaine administration in detoxification of opioid‐dependent individuals: a descriptive open‐label observational study. Addiction 117:1, pages 118-128.
Crossref
Crossref
Kerri Rea & Bruce Wallace. (2021) Enhancing equity-oriented care in psychedelic medicine: Utilizing the EQUIP framework. International Journal of Drug Policy 98, pages 103429.
Crossref
Crossref
Kristin Waters. (2021) Pharmacologic Similarities and Differences Among Hallucinogens. The Journal of Clinical Pharmacology 61:S2.
Crossref
Crossref
Martie S. Underwood, Stephen J. Bright & B. Les Lancaster. (2021) A narrative review of the pharmacological, cultural and psychological literature on ibogaine. Journal of Psychedelic Studies 5:1, pages 44-54.
Crossref
Crossref
Joaquín González, Matias Cavelli, Santiago Castro-Zaballa, Alejandra Mondino, Adriano B. L. Tort, Nicolás Rubido, Ignacio Carrera & Pablo Torterolo. (2021) EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat. ACS Pharmacology & Translational Science 4:2, pages 517-525.
Crossref
Crossref
Shreyas Bhat, Daryl A. Guthrie, Ameya Kasture, Ali El-Kasaby, Jianjing Cao, Alessandro Bonifazi, Therese Ku, JoLynn B. Giancola, Thomas Hummel, Michael Freissmuth & Amy Hauck Newman. (2020) Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters. ACS Pharmacology & Translational Science 4:2, pages 503-516.
Crossref
Crossref
Rishab N. Iyer, David Favela, Guoliang Zhang & David E. Olson. (2021) The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs. Natural Product Reports 38:2, pages 307-329.
Crossref
Crossref
Lindsay P. Cameron, Robert J. Tombari, Ju Lu, Alexander J. Pell, Zefan Q. Hurley, Yann Ehinger, Maxemiliano V. Vargas, Matthew N. McCarroll, Jack C. Taylor, Douglas Myers-Turnbull, Taohui Liu, Bianca Yaghoobi, Lauren J. Laskowski, Emilie I. Anderson, Guoliang Zhang, Jayashri Viswanathan, Brandon M. Brown, Michelle Tjia, Lee E. Dunlap, Zachary T. Rabow, Oliver Fiehn, Heike Wulff, John D. McCorvy, Pamela J. Lein, David Kokel, Dorit Ron, Jamie Peters, Yi Zuo & David E. Olson. (2020) A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589:7842, pages 474-479.
Crossref
Crossref
Gabriela Manzano-Nieves & Conor Liston. (2020) Psychedelics re-engineered for potential use in the clinic. Nature 589:7842, pages 358-359.
Crossref
Crossref
Claire Wilson, Trevor Millar & Zak Matieschyn. (2021) Novel treatment of opioid use disorder using ibogaine and iboga in two adults. Journal of Psychedelic Studies 4:3, pages 149-155.
Crossref
Crossref
Manoj K. Doss, Darrick G. May, Matthew W. Johnson, John M. Clifton, Sidnee L. Hedrick, Thomas E. Prisinzano, Roland R. Griffiths & Frederick S. Barrett. (2020) The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain. Scientific Reports 10:1.
Crossref
Crossref
Michaela Barber, John Gardner, Michael Savic & Adrian Carter. (2020) Ibogaine therapy for addiction: Consumer views from online fora. International Journal of Drug Policy 83, pages 102857.
Crossref
Crossref
Joost J. Breeksema, Alistair R. Niemeijer, Erwin Krediet, Eric Vermetten & Robert A. Schoevers. (2020) Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies. CNS Drugs 34:9, pages 925-946.
Crossref
Crossref
Paola Rodrı́guez, Jessika Urbanavicius, José Pedro Prieto, Sara Fabius, Ana Laura Reyes, Vaclav Havel, Dalibor Sames, Cecilia Scorza & Ignacio Carrera. (2020) A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats. ACS Chemical Neuroscience 11:11, pages 1661-1672.
Crossref
Crossref
A Benjamin Srivastava, John J Mariani & Frances R Levin. (2020) New directions in the treatment of opioid withdrawal. The Lancet 395:10241, pages 1938-1948.
Crossref
Crossref
Felix Krengel, Jonathan Dickinson, Christopher Jenks & Ricardo Reyes‐Chilpa. (2020)
Quantitative Evaluation of a Mexican and a Ghanaian
Tabernaemontana
Species as Alternatives to
Voacanga africana
for the Production of Antiaddictive Ibogan Type Alkaloids
. Chemistry & Biodiversity 17:5.
Crossref
Crossref
Alan K. Davis, Lynnette A. Averill, Nathan D. Sepeda, Joseph P. Barsuglia & Timothy Amoroso. (2020) Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic Stress 4, pages 247054702093956.
Crossref
Crossref
James Grogan, Roy Gerona, Jerry W. Snow & Louise Kao. (2019) Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias. The Journal of Emergency Medicine 57:4, pages e99-e104.
Crossref
Crossref
Matteo Polit, Fabio Friso & Jacques Mabit. (2019) Plant based assisted therapy for the treatment of substance use disorders part 2 : beyond blurred boundaries.. Cultura y Droga 24:28, pages 19-42.
Crossref
Crossref
Jamilah R. George, Timothy I. Michaels, Jae Sevelius & Monnica T. Williams. (2019) The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion. Journal of Psychedelic Studies 4:1, pages 4-15.
Crossref
Crossref
Ingvar R. Möller, Marika Slivacka, Anne Kathrine Nielsen, Søren G. F. Rasmussen, Ulrik Gether, Claus J. Loland & Kasper D. Rand. (2019) Conformational dynamics of the human serotonin transporter during substrate and drug binding. Nature Communications 10:1.
Crossref
Crossref
Soledad Marton, Bruno González, Sebastián Rodríguez-Bottero, Ernesto Miquel, Laura Martínez-Palma, Mariana Pazos, José Pedro Prieto, Paola Rodríguez, Dalibor Sames, Gustavo Seoane, Cecilia Scorza, Patricia Cassina & Ignacio Carrera. (2019) Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Frontiers in Pharmacology 10.
Crossref
Crossref
Esther Blessing, Sanya Virani & John Rotrosen. 2020. Substance Use Disorders. Substance Use Disorders
167
202
.
Michael J. Wasko, Paula A. Witt-Enderby & Christopher K. Surratt. (2018) DARK Classics in Chemical Neuroscience: Ibogaine. ACS Chemical Neuroscience 9:10, pages 2475-2483.
Crossref
Crossref
Eduardo Ekman Schenberg. (2018) Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology 9.
Crossref
Crossref
Deborah C. Mash, Linda Duque, Bryan Page & Kathleen Allen-Ferdinand. (2018) Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. Frontiers in Pharmacology 9.
Crossref
Crossref
Christian Sueur. (2018) État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21 e siècle. Psychotropes Vol. 23:3, pages 125-163.
Crossref
Crossref
. (2018) Ibogaine. Reactions Weekly 1690:1, pages 111-111.
Crossref
Crossref
John Martin Corkery. 2018. Psychedelic Neuroscience. Psychedelic Neuroscience
217
257
.
Joseph P. Barsuglia, Martin Polanco, Robert Palmer, Benjamin J. Malcolm, Benjamin Kelmendi & Tanya Calvey. 2018. Psychedelic Neuroscience. Psychedelic Neuroscience
121
158
.